Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 09, 2021 at 08:11 am EDT
Share
Heron Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 60.469 million compared to USD 55.749 million a year ago. Net loss was USD 61.015 million compared to USD 55.190 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.61 a year ago. For the half year, operating loss was USD 112.583 million compared to USD 108.483 million a year ago. Net loss was USD 113.629 million compared to USD 106.769 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 1.18 a year ago.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
HERON THERAPEUTICS, INC. 
